Search the Newsreel

Telix Pharmaceuticals reports Q2 revenue of US$247M

Telix Pharmaceuticals (ASX:TLX) reported US$247 million in group revenue for Q2 2026, marking a 21% increase year-over-year. This growth was primarily driven by strong performance in its precision medicine unit, particularly Gozellix and the PSMA imaging portfolio. The company projects full-year 2026 revenue to …

Telix Q2 revenue rises 21% YoY to US$247 million

Telix Pharmaceuticals Limited announced a 21% year-over-year increase in Q2 2026 revenue, reaching US$247 million, primarily driven by Precision Medicine growth. The company has revised its FY 2026 revenue outlook to over US$1 billion and increased its R&D guidance to US$230 million–US$270 million. Key …

Telix Pharmaceuticals posts 21% increase in Q2 revenue, tracks top end of full year guidance

Telix Pharmaceuticals announced a 21% year-on-year increase in Q2 group revenue to USD247 million, driven by strong demand in its prostate imaging portfolio. The company is on track to meet the higher end of its full-year guidance, forecasting revenue in excess of USD1 billion, …

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has initiated its Phase 3 LUTEON trial for TLX250-Tx, a targeted radiopharmaceutical therapy for relapsed or recurrent clear cell renal cell carcinoma (ccRCC), by dosing the first patient. This study is notable as the first Phase 3 radiopharmaceutical …

ASX Preview: Australian Shares to Fall as Oil Gains on Middle East Tensions; Telix Pharmaceuticals Posts Higher Q2 Revenue

Telix Pharmaceuticals trails ASX 200 by 8.3 points; Japan remains beyond guidance

Telix Pharmaceuticals (ASX:TLX; NASDAQ:TLX) underperformed the ASX 200, seeing an 8.36% decline over five sessions, including a 4.48% drop on Friday. This occurred despite progress in its Japan Phase 3 enrollment for Illuccix, which is still awaiting conditional approval and is excluded from Telix's …

Telix Pharmaceuticals Completes Phase Three Enrollment for Prostate Cancer Imaging Study in Japan

Telix Pharmaceuticals has successfully completed the enrollment of patients for its Phase III ProstACT GLOBAL study in Japan, evaluating diagnostic imaging for prostate cancer. This milestone is a crucial step for the company's regulatory submission strategy in Japan. The study focuses on patients with …

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

Telix Pharmaceuticals has announced the completion of patient enrollment in its pivotal Phase 3 registration study for TLX591-Px (Illuccix®) in Japan, targeting prostate cancer imaging. The study, involving 105 patients, aims to evaluate the detection efficacy and safety of 68Ga-PSMA-11 PET/CT in Japanese men …

Telix opens radiopharmaceutical facility in Australia for cancer treatment

Telix Pharmaceuticals has opened a new radiopharmaceutical facility in Melbourne, Australia, to accelerate the development and delivery of cancer treatments. The facility integrates research, manufacturing, and patient treatment services to shorten the time from trials to patient access. It also aims to boost Australia's …

Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment

Telix Pharmaceuticals has started dosing patients in its Phase 2 OPTIMAL-e study, evaluating the next-generation PSMA radioligand therapy TLX597-Tx for metastatic hormone-sensitive prostate cancer. The study, led by Professor Louise Emmett at St Vincent's Hospital Sydney, aims to assess an adaptive treatment strategy to …

Telix opens Australian-first facility to accelerate delivery of new cancer treatments

Telix Pharmaceuticals has opened a multi-million dollar radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia. This facility is the first of its kind in Australia, integrating radiochemistry laboratories, clinical product manufacturing, patient dose administration, and imaging under one roof. It aims to accelerate …

Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer

Telix Pharmaceuticals, in collaboration with St Vincent’s Hospital Sydney, has dosed the first patients in its Phase 2 OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The trial evaluates TLX597-Tx, a PSMA-targeting radioligand therapy, in combination with standard treatments, aiming to assess its efficacy …

Citi Sees Positive Catalysts for Telix Pharmaceuticals -- Market Talk

Citi maintains a buy rating on Telix Pharmaceuticals, citing several upcoming positive catalysts for the company. These catalysts include the launch of Illuccix in Canada, regulatory submissions in the EU and UK, potential inclusion in the ASX200 index, and the release of new clinical …

Telix Pharmaceuticals (ASX:TLX) Pulls Back: Is the Healthcare Growth Trade Cooling?

Telix Pharmaceuticals Limited (TLX) heads into June 25 earnings with mixed technical backing

The radiopharmaceuticals developer has risen across recent weekly windows, but relative strength remains negative into the report.

Telix Pharmaceuticals Limited (TLX) approaches earnings with momentum split

The radiopharmaceuticals developer reports on June 18 with a recent weekly gain set against a weaker four-week tape.

Telix Pharmaceuticals Limited (TLX) enters earnings week with weak relative strength

The oncology radiopharmaceuticals developer has recovered over 12 weeks, but its shorter-term tape remains uneven before the June 18 report.

Telix Pharmaceuticals (ASX:TLX): Is This ASX Biotech Stock a Buy Opportunity

Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision?

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure

Telix Pharmaceuticals (ASX:TLX) Stock Jumps 5.89%: FDA Resubmission Fuels Investor Optimism

Why Telix Pharmaceuticals (ASX:TLX) Stock Is Surging Today: Key Catalysts Investors Should Know

Telix Pharmaceuticals Share Jump as Revenue Growth Erases Half of 2026 Losses

Why Telix Pharmaceuticals (ASX:TLX) Is Up 19.1% After 2026 Guidance, Shelf Filing And TLX101-Px Milestone – And What's Next

Stock of the day: Telix Pharmaceuticals

Telix Pharmaceuticals Shares Upgraded: Decline Creates Compelling Entry Point

The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

Telix Pharmaceuticals: The nuclear option

We Think You Can Look Beyond Telix Pharmaceuticals' (ASX:TLX) Lackluster Earnings

Talanx mit Rekordgewinn: Allianz-Konkurrent erhöht Dividende – plus 15 Prozent und bald noch mehr?

Talanx AG: Konsensus der Analysten und Kursziel | TLX100 | DE000TLX1005

TALANX AKTIE Dividende | Hauptversammlung | Dividendenrendite | TLX100

Talanx AG (TLX.DE) Aktienkurs, Nachrichten, Kurs und Verlauf